376
|
Guan H, Jin J. SU-E-J-43: Scatter and Beam Hardening Corrections for MV-CBCT Using a Few MLC Leaf-Pairs and a Cylindrical Water Equivalent Phantom. Med Phys 2013. [DOI: 10.1118/1.4814255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
377
|
Li H, Kim J, Gordon J, Jin J, Huang Y, Chin K, Wen N, Chetty I, Ryu S. SU-E-T-416: Targeting Accuracy of a TrueBeam System for Multi-Lesion Cranial Radiosurgery with Single Isocenter. Med Phys 2013. [DOI: 10.1118/1.4814850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
378
|
Zou G, Chetty I, Jin J. SU-E-J-05: Intrinsic Geometry Reconstruction for the Study of Geometric Variations in Linac-Based CBCT System. Med Phys 2013. [DOI: 10.1118/1.4814217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
379
|
Chin K, Wen N, Huang Y, Jin J, Chetty I, Ryu S. MO-F-108-05: Treatment Planning Study of Volumetric Arc Therapy for Spine Stereotactic Radiosurgery Using Flattening Filter Free Beams. Med Phys 2013. [DOI: 10.1118/1.4815281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
380
|
Zhao WC, Jin J, Zhang JZ. Insulin autoimmune syndrome induced by methimazole in a patient with Graves' disease. J Endocrinol Invest 2013; 36:450-1. [PMID: 23817229 DOI: 10.1007/bf03347108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
381
|
Zou G, Ren L, Kim J, Jaffray D, Chetty I, Jin J. WE-G-141-07: Feasibility of Using a Grid to Detect and Correct the Geometric Variations in Flat-Panel Based Cone Beam CT. Med Phys 2013. [DOI: 10.1118/1.4815658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
382
|
Zhao B, Jin J, Wen N, Chetty I, Ryu S. SU-E-T-478: Prescription to 50-75% Isodose Line May Be Optimum for Linac Radiosurgery of Cranial Lesions. Med Phys 2013. [DOI: 10.1118/1.4814911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
383
|
Hou Y, Chu M, Du FF, Lei JY, Chen Y, Zhu RY, Gong XH, Ma X, Jin J. Recombinant disintegrin domain of ADAM15 inhibits the proliferation and migration of Bel-7402 cells. Biochem Biophys Res Commun 2013; 435:640-5. [PMID: 23688428 DOI: 10.1016/j.bbrc.2013.05.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Accepted: 05/09/2013] [Indexed: 11/27/2022]
Abstract
ADAM15 (A Disintegrin And Metalloproteinase 15), a transmembrane protein containing seven domains, interacts with some integrins via its disintegrin domain and overexpresses in many solid tumors. In this study, the effect of the recombinant human disintegrin domain (rhddADAM15) on the proliferation and migration of Bel-7402 cells was evaluated in vitro and in vivo in zebrafish xenografts. rhddADAM15 (4 μM) severely inhibited the proliferation and migration of Bel-7402 cells, inducing a partial G2/S arrest and morphological nucleus changes of apoptosis. Moreover, the activity of caspases 8, 9 and 3 in Bel-7402 cells was increased. In addition, the zebrafish was used as a model for apoptosis-induction and tumor-xenograft. rhddADAM15 (1 pM) inhibited the growth and metastasis of Bel-7402 cell xenografts in zebrafish and a lower concentration (0.1 pM) induced severe apoptosis in the somatic cells of zebrafish. In conclusion, our data identified rhddADAM15 as a potent inhibitor of tumor growth and metastasis, making it a promising tool for use in anticancer treatment.
Collapse
|
384
|
Tong H, Hu C, Li K, Mei C, Zhuang Z, Ye L, Lu D, Jin J. P-285 LB1, targeting inhibiting protein phosphatase 2A (PP2A), enhances daunorubicin suppression of MDS cell line (SKM-1) in vitro and in vivo. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70332-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
385
|
Amirzada MI, Jin J. Therapeutic Applications of Interleukin 24 (IL24): A Review. TROP J PHARM RES 2013. [DOI: 10.4314/tjpr.v11i6.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
386
|
Jin J, Xu Y, Wang H, Huang H, He Q, Wu P, Chen J. Peritubular capillaritis in early renal allograft dysfunction is an indicator of acute rejection. Transplant Proc 2013; 45:163-71. [PMID: 23375292 DOI: 10.1016/j.transproceed.2012.08.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Revised: 07/25/2012] [Accepted: 08/08/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND Kidneys showing acute rejection (AR) processes often are accompanied by various levels of peritubular capillaritis (Ptc), especially cases of acute humoral rejection (AHR). However, it is not known whether the presence of Ptc alone is sufficient evidence of allograft rejection. This study was performed to determine the diagnostic value of Ptc as a marker for AR among cases of early renal allograft dysfunction. METHODS Fifty-three AR showed C4d deposition in the peritubular capillaries (PTCs; C4d+AR group), 50 AR were without C4d deposition (C4d-AR group), 30 had Ptc alone (Ptc group), 28 had acute tubular necrosis (ATN group), and 78 were surveillance biopsies (control group). RESULTS Analyzing the immunophenotype of infiltrating T lymphocytes and serum antibodies, discovered that 85.9% of control biopsies presented with a regulatory phenotype. Among the Ptc cohort, 93.3% of biopsies showed the cytotoxic phenotype with no significant different between C4d+AR and C4d-AR (96.2% vs 92.0%). We also observed the prevalence of panel-reactive antibody (PRA) and major-histocompatibility-complex class I chain-related gene A (MICA) antibodies to be increased among Ptc (30.0% and 43.3%, respectively), albeit not significantly different from C4d+AR (49.1% and 39.6%, respectively). The prevalences were low in other groups. CONCLUSIONS These results implied that Ptc in biopsy specimens from patients with early renal allograft dysfunction was an indicator of AR, especially AHR.
Collapse
|
387
|
Liu H, Chu K, Ochoa AE, Ye Z, Zhang X, Jin J, Wright MC, Barsky SH, Cristofanilli M, Robertson FM. Abstract P6-10-04: The Presence of Anaplastic Lymphoma Kinase Recapitulates Formation of Breast Tumor Emboli with Encircling Lymphovasculogenesis. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Genetic abnormalities in the anaplastic lymphoma kinase (ALK) gene result in activation of signaling pathways including Akt, mTor, and JAK/Stat3. ALK has been shown to be a primary oncogenic driver in a variety of human tumors, including both hematologic malignancies such as anaplastic large cell lymphoma, as well as solid tumors including neuroblastoma, non-small cell lung cancer, myofibroblastic tumors and most recently, high grade serous ovarian carcinoma. While only ∼3% of all breast cancers have been reported to have ALK genetic abnormalities, our studies revealed that inflammatory breast cancer (IBC), the most lethal variant of breast cancer, is characterized by prevalent ALK gene amplification with activated ALK signaling. The present studies investigated the role of ALK in breast cancer by expressing full-length wild type ALK in MCF-7 cells.
Materials and Methods: Clones of MCF-7 breast cancer cells expressing wild type ALK or non-target vector were produced by lentivirus infection and selection of single cell clones. MCF-7 ALK clones were evaluated using live cell and phase contrast imaging, immunofluorescent staining with confocal imaging, gene profiling, phospho-protein array analysis, western blot and ELISA validation. In vivo studies were performed by injection of MCF-7 ALK clones into using NOD. Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice using IACUC approved animal protocols.
Results: When cultured on plastic substrates, MCF-7 ALK clones formed tumor cell aggregates instead of monolayer cultures, and when cultured as tumor spheroids under non-adherent 3D conditions had a distinct cellular phenotype with significantly greater clonogenicity than either non-target vector MCF-7 clones or the parental cell line. Whole transcriptome analysis, with validation using protein arrays, western blots and ELISA analysis revealed that the presence of ALK up-regulated phospho-src. In vivo studies revealed that ALK expressing MCF-7 clones formed tumor emboli that were enwrapped by dermal lymphatic vessels, essentially recapitulating the phenotype of IBC tumor emboli that exhibit encircling lymphovasculogenesis. Enforced expression of wild type ALK in another breast cancer cell line resulted in similar formation of tumor emboli.
Discussion: These studies provide first time evidence for the association between full length ALK and formation of highly invasive tumor emboli enwrapped by lymphatic vessels, which is a primary characteristic of IBC. These studies, taken together with discovery of the prevalence of ALK gene amplification in IBC patients, indicate that ALK represents an important therapeutic target for IBC, with the availability of new ALK targeted therapies to evaluate as single agents and in combinations with other agents that may effectively target IBC tumor emboli that we have now linked to ALK and which represent the metastatic lesion of this lethal variant of breast cancer.
Funding by Susan G. Komen Organization Promise Grant KG081287 (FMR and MC).
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-10-04.
Collapse
|
388
|
Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin J. Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-18-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Trastuzumab emtansine (T-DM1) is a HER2-targeted antibody-drug conjugate composed of the humanized monoclonal antibody trastuzumab, the potent cytotoxic agent DM1 (a microtubule inhibitor), and a stable thioether linker. To estimate typical pharmacokinetic (PK) parameter values and interpatient variability, a population PK model for T-DM1 was previously developed from 1 phase 1 (0.3 to 4.8 mg/kg in qw or q3w regimens) and 2 phase 2 (3.6 mg/kg q3w) trials (Gupta, J Clin Pharmacol 2012). The model reported here has been updated with additional data from 2 randomized trials (phase 2 TDM4450g and phase 3 EMILIA, 3.6 mg/kg q3w). Another phase 2 trial (TDM4688g) was used for external validation of the model. The effect of demographic and pathophysiological covariates on the PK of T-DM1 was explored to better understand the clinical factors that might affect exposure and clinical outcome for individual patients.
Methods: For the current analysis, 9934 T-DM1 serum concentration-time data points from 671 patients were simultaneously fitted using NONMEM® software. T-DM1 concentration-time data to date are best described using a 2-compartment linear model. All relevant and plausible covariates likely to have an effect on T-DM1 systemic exposure, or likely to have clinical relevance, were explored for possible correlation with the key T-DM1 PK parameters of clearance (CL) and central volume of distribution (Vc). These covariates include those related to demographics, renal and hepatic function, disease status, and treatment history.
Results: The estimated CL for T-DM1 is 0.68 L/day, Vc is 3.13 L, and the terminal half-life is 3.94 days. Interindividual variability (IIV) of the base model is 25.6% and 17.5% for CL and Vc, respectively. Patients with greater body weight, sum of longest dimension of target lesions, serum concentration of shed HER2 extracellular domain, and aspartate aminotransferase concentrations, as well as patients with lower serum albumin and baseline trastuzumab concentrations, have statistically faster CL. Patients with greater body weight also have statistically larger Vc. Incorporation of these covariates (P<0.001 by likelihood ratio test) decreased IIV of CL and Vc to 19.1% and 11.7%, respectively. All covariates together explain 44.4% and 55.8% of IIV in CL and Vc, respectively. The model sensitivity analysis suggests that a patient with a statistically significant PK covariate value at the 5th or 95th percentile of the population will have a <20% difference in cumulative exposure (as represented by area under the T-DM1 concentration-time curve) compared with a typical patient with a median covariate value.
Conclusions: A relatively small IIV for the estimated T-DM1 PK parameters of CL and Vc was observed. None of the evaluated covariates had a clinically meaningful magnitude of effect on T-DM1 exposure (<20% difference for patients with 5th and 95th percentiles vs patients with median value of covariates) that would justify a further dose adjustment. The body weight–based dose of 3.6 mg/kg q3w without further correction for other factors is considered appropriate in ongoing clinical trials.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-24.
Collapse
|
389
|
Adare A, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom JH, Blau DS, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Caringi A, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa Del Valle Z, Connors M, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Issah M, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DJ, Kim EJ, Kim YJ, Kinney E, Kiss A, Kistenev E, Kleinjan D, Kochenda L, Komkov B, Konno M, Koster J, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Leitch MJ, Leite MAL, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Miki K, Milov A, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zhou S. Cold-nuclear-matter effects on heavy-quark production in d+Au collisions at sqrt[S(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:242301. [PMID: 23368311 DOI: 10.1103/physrevlett.109.242301] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Indexed: 06/01/2023]
Abstract
The PHENIX experiment has measured electrons and positrons at midrapidity from the decays of hadrons containing charm and bottom quarks produced in d+Au and p+p collisions at sqrt[S(NN)]=200 GeV in the transverse-momentum range 0.85 ≤ p(T)(e) ≤ 8.5 GeV/c. In central d+Au collisions, the nuclear modification factor R(dA) at 1.5<p(T)<5 GeV/c displays evidence of enhancement of these electrons, relative to those produced in p+p collisions, and shows that the mass-dependent Cronin enhancement observed at the Relativistic Heavy Ion Collider extends to the heavy D meson family. A comparison with the neutral-pion data suggests that the difference in cold-nuclear-matter effects on light- and heavy-flavor mesons could contribute to the observed differences between the π(0) and heavy-flavor-electron nuclear modification factors R(AA).
Collapse
|
390
|
Ren H, Jin J, Li Y, Wang X, Li N. Preliminary Results of Ongoing Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) Combined With Capecitabine for High-risk Gastric Cancer Patients. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.826] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
391
|
Zhang X, Li Y, Wang S, Wang W, Jin J, Liu Y, Song Y, Liu X, Zhou L, Yu Z. Clinical Features and Treatment Outcomes of Patients With Primary Systemic Anaplastic Large Cell Lymphoma: Report From a Single Institution in China. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
392
|
Zhao T, Li Y, Wang S, Wang W, Jin J, Song Y, Liu Y, Liu X, Yu Z. Radiation Therapy Improves the Prognosis of Locoregionally Recurrent Extranodal Nasal-type NK/T-cell Lymphoma. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
393
|
Wu R, Li Y, Liu Q, Wang W, Jin J, Zhang X, Lu N, Qi S, Liu X, Yu Z. Patterns of Local Extension and Regional Spread in Early Stage Nasal NK/T-cell Lymphoma Based on Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
394
|
Li N, Jin J, Li Y. Phase I Clinical Study of Concurrent Chemoradiation With Hydroxycamptothecin for Unresectable or Locally Relapsed Rectal Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
395
|
Jin J, Zhao B, Li H, Kim J, Glide-Hurst C, Brown S, Movsas B, Ryu S, Chetty I, Kong F. A Novel Multifield Grid Treatment Technique Using MLC-based IMRT. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.2309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
396
|
Zhang X, Li Y, Wang S, Wang W, Jin J, Liu Y, Song Y, Liu X, Zhou L, Yu Z. Outcomes of ALK-negative Anaplastic Large Cell Lymphoma are Superior to Peripheral T-cell Lymphoma, Not Otherwise Specified: Report From a Single Chinese Institution. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.1647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
397
|
Peng R, Wang S, Li Y, Song Y, Wang W, Jin J, Liu Y, Liu X, Yu Z, Ren H. Intensity Modulated Radiation Therapy With Integrated Boost After Breast Conservative Surgery in Breast Cancer Patients: A Prospective Study. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
398
|
Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Jamel A, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Chujo T, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Das K, David G, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Enokizono A, En'yo H, Espagnon B, Esumi S, Fields DE, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fukao Y, Fung SY, Gadrat S, Gastineau F, Germain M, Glenn A, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haggerty JS, Hagiwara MN, Hamagaki H, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, He X, Heffner M, Hemmick TK, Heuser JM, Hiejima H, Hill JC, Hobbs R, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hur MG, Ichihara T, Iinuma H, Imai K, Imrek J, Inaba M, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kaneta M, Kang JH, Kawagishi T, Kazantsev AV, Kelly S, Khanzadeev A, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Kroon PJ, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Leitch MJ, Leite MAL, Li XH, Lim H, Litvinenko A, Liu MX, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Masui H, Matathias F, McCain MC, McGaughey PL, Miake Y, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mitchell JT, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakamura T, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Ogilvie CA, Ohnishi H, Ojha ID, Okada K, Omiwade OO, Oskarsson A, Otterlund I, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Ravinovich I, Read KF, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Samsonov V, Sato HD, Sato S, Sawada S, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Sim KS, Singh CP, Singh V, Skutnik S, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Tojo J, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vértesi R, Vinogradov AA, Vznuzdaev E, Wagner M, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yanovich A, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zimányi J, Zolin L. Measurement of direct photons in Au+Au collisions at √(s(NN))=200 GeV. PHYSICAL REVIEW LETTERS 2012; 109:152302. [PMID: 23102300 DOI: 10.1103/physrevlett.109.152302] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2012] [Indexed: 06/01/2023]
Abstract
We report the measurement of direct photons at midrapidity in Au+Au collisions at √(s(NN))=200 GeV. The direct photon signal was extracted for the transverse momentum range of 4 GeV/c<p(T)<22 GeV/c, using a statistical method to subtract decay photons from the inclusive photon sample. The direct photon nuclear modification factor R(AA) was calculated as a function of p(T) for different Au+Au collision centralities using the measured p+p direct photon spectrum and compared to theoretical predictions. R(AA) was found to be consistent with unity for all centralities over the entire measured p(T) range. Theoretical models that account for modifications of initial direct photon production due to modified parton distribution functions in Au and the different isospin composition of the nuclei predict a modest change of R(AA) from unity. They are consistent with the data. Models with compensating effects of the quark-gluon plasma on high-energy photons, such as suppression of jet-fragmentation photons and induced-photon bremsstrahlung from partons traversing the medium, are also consistent with this measurement.
Collapse
|
399
|
Mao L, Shi G, Tian Y, Liu H, Jin L, Yamamoto K, Tao S, Jin J. A novel thin-layer amperometric detector based on chemically modified ring-disc electrode and its application for simultaneous measurements of nitric oxide and nitrite in rat brain combined with in vivo microdialysis. Talanta 2012; 46:1547-56. [PMID: 18967286 DOI: 10.1016/s0039-9140(98)00027-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/1997] [Revised: 01/06/1998] [Accepted: 01/08/1998] [Indexed: 10/18/2022]
Abstract
A novel thin-layer amperometric detector (TLAD) based on chemically modified ring-disc electrode and its application for simultaneous measurements of nitric oxide (NO) and nitrite (NO(2)(-)) in rat brain were demonstrated in this work. The ring-disc electrode was simultaneously sensitive to nitric oxide (NO) and nitrite (NO(2)(-)) by modifying its inner disc with electropolymerized film of cobalt(II) tetraaminophthalocyanine (polyCoTAPc)/Nafion and its outer ring with poly(vinylpyridine) (PVP), respectively. The ring-disc electrode was used to constitute a novel TLAD in radial flow cell for simultaneous measurements of NO and NO(2)(-) in rat brain combined with techniques of high performance liquid chromatography (HPLC) and in vivo microdialysis. It was found that the basal concentration of NO in the caudate nucleus of rat brain is lower than 1.0x10(-7) mol l(-1), NO(2)(-) concentration is 5.0x10(-7) mol l(-1) and NO exists in brain maybe mainly in the form of its decomposed product.
Collapse
|
400
|
Jin J, Zhang Y, Fan X, Diao N, Shao L, Wang F, Hu P, Wang S, Weng X, Zhang W. Evaluation of the GenoType® MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection. Int J Tuberc Lung Dis 2012; 16:521-6. [PMID: 22325117 DOI: 10.5588/ijtld.11.0269] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE To assess the new GenoType® MTBDRplus assay for the rapid detection of multidrug-resistant tuberculosis (MDR-TB) in comparison with DNA sequencing to identify drug resistance mutation profiles in China. DESIGN Using MTBDRplus, drug susceptibility testing (DST) and DNA sequencing, 237 Mycobacterium tuberculosis strains were tested. RESULTS The sensitivity of MTBDRplus was 75.0% (126/168) for isoniazid (INH) resistant strains, and 93.5% (157/168) for rifampicin (RMP) resistant strains. It correlated well with sequencing, with 94.9% and 99.6% agreement for each strain category and 100% specificity for all categories. The two most common rpoB mutations were S531L (53.6%, 90/168) and D516G (17.3%, 29/168) in RMP-resistant strains. INH resistance was dominated by the katG 315 locus (S to T, N, R, I) mutation (73.7%, 124/168), and a rare katG mutation, S315N (6.5%, 11/168), not covered by MTBDRplus was identified. The mutation combination inhA-15/inhA-8 and katG315 (34 strains) was characteristically displayed in MDR-TB strains (23.5%), but not in INH-monoresistant strains. CONCLUSIONS Although Genotype MTBDRplus is a rapid and reliable molecular test for detecting MDR-TB, a significant proportion of strains in China contain a rare katG S315N mutation that would be missed by the assay. Further improvements may be achieved by incorporating this mutation into the assay to increase sensitivity in detecting INH resistance in China.
Collapse
|